


**“Should federal order reform change classified pricing to less than four classes?”**

**PD**

**POLL**



## NATIONAL RESULTS



**Bob Cropp**


Professor Emeritus and Dairy Marketing Specialist, University of Wisconsin – Madison  
racropp@wisc.edu

This vote is not surprising. Dairy producers are frustrated over the volatility in milk prices. Some producers feel that outdated provisions of federal milk marketing orders may actually contribute to price volatility and lack price transparency.


Further, many are aware of proposals by National Milk Producers Federation and others to change federal orders, one of which is to reduce the number of classes. Some producers question why the price received for milk used to make cheese differs from milk used to make butter/powder. These producers feel that the competition for milk to make manufactured dairy products ought to result in one price for manufacturing-use milk.

Producers who voted no to fewer classes of milk are most likely concerned that it could reduce the average producer pay price.

## WEST VS. EAST



**WEST RESULTS**



**EAST RESULTS**

## Resources for Your Success

Dairy Grazing Services (DGS), offered as part of Dairy Farmers of America, Inc.'s Farm Services Division, provides the resources you need when looking to incorporate a pasture-based system into your operation.

To learn more about DGS, visit [www.dfamilk.com/grazing](http://www.dfamilk.com/grazing) or call 816-801-6660.



OPERATIONAL SOLUTIONS



ADVTNL1012



Antibiotic  
100 mg of tulathromycin/mL

For subcutaneous injection in beef and non-lactating dairy cattle and intramuscular injection in swine only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

**CAUTION**

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**INDICATIONS**

**Beef and Non-lactating Dairy Cattle**

**BRD** – DRAXXIN Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*; and for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*.

**IBK** – DRAXXIN Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with *Moraxella bovis*.

**Foot Rot** – DRAXXIN Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with *Fusobacterium necrophorum* and *Porphyromonas levilii*.

**Swine**

DRAXXIN Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

**DOSAGE AND ADMINISTRATION**

**Cattle**

Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.

**Swine**

Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

**CONTRAINDICATIONS**

The use of DRAXXIN Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

**WARNINGS**

**FOR USE IN ANIMALS ONLY.**

**NOT FOR HUMAN USE.**

**KEEP OUT OF REACH OF CHILDREN.**

**NOT FOR USE IN CHICKENS OR TURKEYS.**

**RESIDUE WARNINGS**

**Cattle**

Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

**Swine**

Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

**PRECAUTIONS**

**Cattle**

The effects of DRAXXIN on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

**Swine**

The effects of DRAXXIN on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

**ADVERSE REACTIONS**

**Cattle**

In one field study, two calves treated with DRAXXIN at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

**Swine**

In one field study, one out of 40 pigs treated with DRAXXIN at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

**STORAGE CONDITIONS**

Store at or below 25°C (77°F).

**HOW SUPPLIED**

DRAXXIN Injectable Solution is available in the following package sizes: 50 mL vial, 100 mL vial, 250 mL vial, 500 mL vial

U.S. Patents: See US 6,329,345; US 6,420,536; US 6,514,945; US 6,583,274; US 6,777,393

NADA 141-244, Approved by FDA

Distributed by:



Division of Pfizer Inc, NY, NY 10017

To report a suspected adverse reaction call 1-800-366-5288.

To request a material safety data sheet call 1-800-733-5500.

For additional DRAXXIN product information call

1-888-DRAXXIN or go to [www.DRAXXIN.com](http://www.DRAXXIN.com)



Made in France.

79-9949-00-3

December 2009

87 1207 2